The expanding options for front-line treatment in patients with newly diagnosed CML
Critical Reviews in Oncology/Hematology
Javier Pinilla-Ibarz, Ian Flinn -
published online 09 April 2012.
Critical Reviews in Oncology/Hematology
Javier Pinilla-Ibarz, Ian Flinn -
published online 09 April 2012.
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1
Abstract:
Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more
My Approach to Chronic Myeloid Leukemia
Interview by L Scott Zoeller. 2012 Apr 3, Tim Hughes, MD
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 30, S Freeman
Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Leukemia 26, 490-498 (March 2012) | doi:10.1038/leu.2011.231
Leukemia 26, 490-498 (March 2012) | doi:10.1038/leu.2011.231
Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.
Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era.
Elsevier Global Medical News. 2011 Jun 23, S Freeman
Elsevier Global Medical News. 2011 Jun 23, S Freeman
Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Jorge Cortes, January 2012
Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Jorge Cortes, January 2012